MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Isoray Net Income 2011-2025 | ISR
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Isoray
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -79.3 M | -46.5 M | -7.34 M | -3.85 M | -3.45 M | -5.14 M | -6.7 M | -6.16 M | -4.71 M | -3.68 M | -5.96 M | -3.86 M | -3.49 M | -2.84 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.84 M | -79.3 M | -13.1 M |
Quarterly Net Income Isoray
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -26 M | -21.5 M | - | -15.1 M | -11.7 M | -12.3 M | - | -10.4 M | -11.1 M | -371 K | - | -4.07 M | -2.08 M | -1.35 M | -1.6 M | -2.24 M | -1.6 M | -2.24 M | -868 K | -868 K | -868 K | -713 K | -897 K | -897 K | -897 K | -816 K | -1.41 M | -1.41 M | -1.41 M | -1.51 M | -1.46 M | -1.55 M | -1.46 M | -1.55 M | -1.45 M | -1.5 M | -1.45 M | -1.5 M | -1.31 M | -1.02 M | -1.31 M | -1.02 M | -907 K | -786 K | -907 K | -786 K | -927 K | -1.27 M | -927 K | -1.27 M | -1.15 M | -994 K | -1.15 M | -994 K | -629 K | -1.1 M | -629 K | -1.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -371 K | -26 M | -3.06 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical instruments industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Baxter International
BAX
|
-512 M | $ 19.13 | -1.34 % | $ 9.76 B |  USA |
 |
Becton, Dickinson and Company
BDX
|
1.68 B | $ 194.7 | -0.82 % | $ 56 B | USA |
 |
Luminex Corporation
LMNX
|
15.2 M | - | - | $ 1.75 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-11.3 M | $ 5.44 | -2.25 % | $ 110 M | USA |
 |
Akers Biosciences, Inc.
AKER
|
-17.6 M | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
56.2 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
13.7 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
-24.5 M | - | - | $ 282 M | USA |
 |
Harvard Bioscience
HBIO
|
-3.42 M | $ 0.67 | -4.61 % | $ 28.4 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
223 M | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
292 M | - | -0.02 % | $ 16.3 B | USA |
 |
Repro Med Systems
KRMD
|
-13.7 M | $ 6.07 | -2.57 % | $ 277 M | USA |
 |
Alcon
ALC
|
376 M | $ 80.29 | -0.08 % | $ 40.4 B |  Schweiz |
 |
LeMaitre Vascular
LMAT
|
44 M | $ 83.23 | -0.66 % | $ 1.87 B | USA |
 |
iRhythm Technologies
IRTC
|
-113 M | $ 177.48 | 0.5 % | $ 5.54 B | USA |
 |
ICU Medical
ICUI
|
-118 M | $ 147.13 | -0.5 % | $ 3.59 B | USA |
 |
Masimo Corporation
MASI
|
-305 M | $ 131.05 | -1.29 % | $ 6.98 B | USA |
 |
AtriCure
ATRC
|
-44.7 M | $ 40.51 | 0.45 % | $ 1.9 B | USA |
 |
Atrion Corporation
ATRI
|
19.4 M | - | - | $ 810 M | USA |
 |
Merit Medical Systems
MMSI
|
120 M | $ 88.6 | 1.38 % | $ 5.16 B | USA |
 |
electroCore
ECOR
|
-18.8 M | $ 4.86 | -1.82 % | $ 26.8 K | USA |
 |
AngioDynamics
ANGO
|
-34 M | $ 12.88 | -1.68 % | $ 526 M | USA |
 |
The Cooper Companies
COO
|
375 M | $ 82.05 | -0.7 % | $ 16.3 B | USA |
 |
Glaukos Corporation
GKOS
|
-135 M | $ 115.66 | -0.7 % | $ 5.6 B | USA |
 |
Haemonetics Corporation
HAE
|
168 M | $ 80.29 | -0.01 % | $ 4.04 B | USA |
 |
InfuSystem Holdings
INFU
|
18 K | $ 8.81 | -1.67 % | $ 182 M | USA |
 |
OraSure Technologies
OSUR
|
-19.5 M | $ 2.44 | 1.03 % | $ 182 M | USA |
 |
Intuitive Surgical
ISRG
|
2.32 B | $ 574.53 | -0.57 % | $ 204 B | USA |
 |
ResMed
RMD
|
779 M | $ 243.2 | -0.68 % | $ 35.5 B | USA |
 |
Microbot Medical
MBOT
|
-10.7 M | $ 2.09 | -3.02 % | $ 21.3 M |  Israel |
 |
Milestone Scientific
MLSS
|
-4.71 M | $ 0.29 | 1.05 % | $ 23.1 M | USA |
 |
Nephros
NEPH
|
-1.58 M | $ 4.97 | 0.89 % | $ 51.6 M | USA |
 |
NeuroMetrix
NURO
|
-7.81 M | - | 5.05 % | $ 9.02 M | USA |
 |
STERIS plc
STE
|
615 M | $ 256.17 | 0.36 % | $ 25.3 B | USA |
 |
Envista Holdings Corporation
NVST
|
-1.12 B | $ 21.78 | -0.95 % | $ 3.75 B | USA |
 |
Predictive Oncology
POAI
|
-12.7 M | - | - | $ 32.4 M | USA |
 |
Stereotaxis
STXS
|
-20.7 M | $ 2.3 | -6.71 % | $ 186 M | USA |
 |
Pro-Dex
PDEX
|
8.98 M | $ 39.07 | -0.97 % | $ 128 M | USA |
 |
Utah Medical Products
UTMD
|
4.29 M | $ 56.78 | 0.05 % | $ 206 M | USA |
 |
Pulse Biosciences
PLSE
|
-42.2 M | $ 14.15 | -1.74 % | $ 680 M | USA |
 |
Repligen Corporation
RGEN
|
35.6 M | $ 165.8 | -0.25 % | $ 9.24 M | USA |
 |
BioLife Solutions
BLFS
|
-20.2 M | $ 24.98 | 0.32 % | $ 1.15 B | USA |
 |
Retractable Technologies
RVP
|
-11.9 M | $ 0.8 | -4.42 % | $ 23.9 M | USA |
 |
STAAR Surgical Company
STAA
|
-20.2 M | $ 23.6 | 1.07 % | $ 1.16 B | USA |
 |
Teleflex Incorporated
TFX
|
69.7 M | $ 122.43 | -0.3 % | $ 5.73 B | USA |
 |
West Pharmaceutical Services
WST
|
493 M | $ 274.5 | -0.04 % | $ 20 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-910 M | $ 11.25 | -2.39 % | $ 2.29 B | USA |